| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Sales | 12,877 | 11,373 | 9,430 | 11,487 |
| Cost of sales | 4,580 | 4,290 | 3,765 | 4,533 |
| Gross profit | 8,297 | 7,083 | 5,665 | 6,954 |
| Research and development | 801 | 824 | 804 | 1,142 |
| Professional services | 1,481 | 1,621 | 1,449 | 1,648 |
| Salaries and related costs | 3,191 | 3,072 | 3,081 | 3,508 |
| Selling, general and administrative | 3,656 | 4,140 | 3,382 | 4,291 |
| Total other costs and expenses | 9,129 | 9,657 | 8,716 | 10,589 |
| Loss from operations | -832 | -2,574 | -3,051 | -3,635 |
| Other expense, net | - | 0 | - | 24 |
| Interest income | 292 | 278 | 304 | 378 |
| Interest expense | 1,413 | 1,393 | 1,376 | 1,431 |
| Other income, net | 76 | - | - | - |
| Total other expense, net | -1,045 | -1,115 | -1,072 | -1,029 |
| Loss before income taxes | -1,877 | -3,689 | -4,123 | -4,664 |
| Income tax expense | 78 | 49 | 49 | 60 |
| Net loss | -1,955 | -3,738 | -4,172 | -4,724 |
| Net income (loss) attributable to non-controlling interest | 29 | 40 | -22 | -21 |
| Net loss attributable to stockholders | -1,984 | -3,778 | -4,150 | -4,703 |
| Basic and diluted (in dollars per share) | -0.05 | -0.09 | -0.1 | -0.14 |
| Weighted average shares outstanding - basic and diluted (in shares) | 40,748,000 | 40,729,000 | 40,729,000 | 34,644,000 |
Apyx Medical Corp (APYX)
Apyx Medical Corp (APYX)